Hallman M, Bry K, Hoppu K, Lappi M, Pohjavuori M
Children's Hospital, University of Helsinki, Finland.
N Engl J Med. 1992 May 7;326(19):1233-9. doi: 10.1056/NEJM199205073261901.
Inositol influences cellular function and organ maturation. Feeding premature infants inositol-rich breast milk increases their serum inositol concentrations. Whether inositol supplementation benefits infants receiving fluids for parenteral nutrition, which are inositol-free, is not known.
We carried out a placebo-controlled, randomized, double-blind trial to determine the effects of administering inositol (80 mg per kilogram of body weight per day) during the first five days of life to 221 infants with respiratory distress syndrome who were receiving parenteral nutrition (gestational age, 24 to 32 weeks; birth weight, less than 2000 g). All the infants were treated with mechanical ventilation and some with surfactant as well. The primary end point was survival at 28 days without bronchopulmonary dysplasia.
The 114 patients given inositol had significantly lower mean requirements for inspiratory oxygen (P less than 0.01) and mean airway pressure (P less than 0.05) from the 12th through the 144th hour of life than did the 107 infants given placebo. Eighty-one infants given inositol and 51 given placebo survived without bronchopulmonary dysplasia (71 vs. 55 percent; P = 0.005). In the 65 infants given surfactant, however, inositol had no effect on the degree of respiratory failure. Thirteen infants given inositol and 21 given placebo had retinopathy of prematurity (13 vs. 26 percent; P = 0.022); none of the infants given inositol had stage 4 disease, whereas 7 of those given placebo did (0 vs. 9 percent; P = 0.012). Among the infants given placebo, those who had poor outcomes (death, bronchopulmonary dysplasia, or stage 4 retinopathy of prematurity) had lower serum inositol concentrations during days 2 through 7 than those who had good outcomes (P less than 0.01).
The administration of inositol to premature infants with respiratory distress syndrome who are receiving parenteral nutrition during the first week of life is associated with increased survival without bronchopulmonary dysplasia and with a decreased incidence of retinopathy of prematurity.
肌醇影响细胞功能和器官成熟。给早产儿喂食富含肌醇的母乳可提高其血清肌醇浓度。对于接受不含肌醇的肠外营养补液的婴儿,补充肌醇是否有益尚不清楚。
我们进行了一项安慰剂对照、随机、双盲试验,以确定在出生后前五天给221例患有呼吸窘迫综合征且正在接受肠外营养的婴儿(胎龄24至32周;出生体重低于2000 g)给予肌醇(每天每公斤体重80 mg)的效果。所有婴儿均接受机械通气治疗,部分婴儿还接受了表面活性剂治疗。主要终点是28天时存活且无支气管肺发育不良。
从出生后第12小时至第144小时,接受肌醇治疗的114例患者的吸气氧平均需求量(P<0.01)和平均气道压力(P<0.05)显著低于接受安慰剂治疗的107例婴儿。接受肌醇治疗的81例婴儿和接受安慰剂治疗的51例婴儿存活且无支气管肺发育不良(71%对55%;P=0.005)。然而,在65例接受表面活性剂治疗的婴儿中,肌醇对呼吸衰竭程度无影响。接受肌醇治疗的13例婴儿和接受安慰剂治疗的21例婴儿发生早产儿视网膜病变(13%对26%;P=0.022);接受肌醇治疗的婴儿均无4期疾病,而接受安慰剂治疗的婴儿中有7例有4期疾病(0对9%;P=0.012)。在接受安慰剂治疗的婴儿中,预后不良(死亡、支气管肺发育不良或4期早产儿视网膜病变)的婴儿在出生后第2天至第7天的血清肌醇浓度低于预后良好的婴儿(P<0.01)。
在出生后第一周给患有呼吸窘迫综合征且正在接受肠外营养的早产儿给予肌醇,与无支气管肺发育不良的存活率增加以及早产儿视网膜病变的发生率降低相关。